Preoperative Asymptomatic Leucocyturia and Early Prosthetic Joint Infections in Patients Undergoing Joint Arthroplasty
ABSTRACT Prosthetic joint infection (PJI) is associated with a higher mortality, morbidity and economic costs. Although it is well known that the presence of urinary tract infection (UTI) is associated with PJI, few investigations evaluated the preoperative asymptomatic leukocyturia (ASL) and the possible relationship with early PJI. We reviewed the records of 739 patients performed primary joint arthroplasty. A total of 131 patients had preoperative ASL (17.7%) and 7 of 739 patients (0.9%) had early PJI. Preoperative ASL was not confirmed as a risk factor for early PJI on the multivariate regression analysis with an adjusted OR of 1.04 (P>0.05). Therefore, it should not be considered as a reason for postponement of total joint arthroplasty.
SourceAvailable from: unam.mx[Show abstract] [Hide abstract]
ABSTRACT: Asymptomatic bacteriuria is common. Populations with structural or functional abnormalities of the genitourinary tract may have an exceedingly high prevalence of bacteriuria, but even healthy individuals frequently have positive urine cultures. Asymptomatic bacteriuria is seldom associated with adverse outcomes. Pregnant women and individuals who are to undergo traumatic genitourinary interventions are at risk for complications of bacteriuria and benefit from screening and treatment programs. Although screening is recommended for renal transplant recipients, the benefits for these patients are less clear. For other populations, including most bacteriuric individuals, negative outcomes attributable to asymptomatic bacteriuria have not been described. Treatment of asymptomatic bacteriuria in these patients is not beneficial and, in fact, may be associated with harmful outcomes, such as increased short-term frequency of symptomatic infection, adverse drug effects, and reinfection with organisms of increased antimicrobial resistance. Screening for asymptomatic bacteriuria and treatment is recommended for only selected groups where benefit has been shown. Many research questions still need to be addressed. Different populations have unique risk factors, and the benefits and risks of different management approaches for asymptomatic bacteriuria must continue to be addressed systematically in appropriate clinical trials.Infectious Disease Clinics of North America 07/2003; 17(2):367-94. DOI:10.1016/S0891-5520(03)00008-4 · 2.31 Impact Factor
Hypertension 12/2003; 42(5):1050-65. DOI:10.1161/01.HYP.0000102971.85504.7c · 7.63 Impact Factor
Clinical Infectious Diseases 04/2005; 40(5):643-54. DOI:10.1086/427507 · 9.42 Impact Factor